|
|
RALEIGH,
N.C., April 30, 2009: DARA BioSciences, Inc. (Nasdaq:DARA) announced
the appointment of Gail F. Lieberman to its Board of Directors. The
appointment was effective April 27, 2009, and fills a vacancy that had
previously existed on the company's Board.
"I am
pleased to be associated with a company that has significant growth
prospects and offers so much hope through the products it develops,"
commented Ms. Lieberman.
Ms.
Lieberman is the founder and Managing Partner of Rudder Capital, LLC,
which provides financial and strategic advisory services for
middle-market companies including M&A advisory and strategic consulting.
She has been a Chief Financial Officer for Fortune 500 companies:
Thomson Corporation's Financial & Professional Publishing division,
Moody's Investor Service (D&B) and Scali, McCabe, Sloves (Ogilvy Group).
Ms.
Lieberman has recently served as a Director for three public companies
in the healthcare and aerospace sectors: I-Trax Inc. (Amex:DMX), Chair
of Audit Committee, Member of Compensation and Strategy Committees,
2004-2008; TriPath Imaging Inc. (Nasdaq:TPTH), Member of Audit and
Governance Committees, 2005-2006; Breeze-Eastern Corporation (Amex:BZC),
Chair of Audit Committee, Member of Strategy Committee, 2005-2007.
Ms.
Lieberman holds a BA in Mathematics and Physics and an MBA in Finance
from Temple University.
About
DARA BioSciences, Inc.
DARA is a
Raleigh, North Carolina-based development-stage pharmaceutical company
that acquires and develops promising drug candidates. DARA focuses its
therapeutic development efforts on small molecules from late preclinical
development through phase 2 clinical trials. DARA has a portfolio of
drug candidates for neuropathic pain, type 2 diabetes, and psoriasis.
For more information, please contact the Company at 919-872-5578 or
visit our web site at
www.darabio.com.
All
statements in this news release that are not historical are
forward-looking statements within the meaning of the Securities Exchange
Act of 1934 as amended. Such forward-looking statements are subject to
factors that could cause actual results to differ materially for DARA
from those projected. Those factors include risks and uncertainties
relating to DARA's ability to regain compliance with NASDAQ continued
listing requirements, DARA's current cash position and its need to raise
additional capital in the near term in order to be able to continue
operations, DARA's ability to develop and bring new products to market
as anticipated, the current regulatory environment in which the Company
develops and sells its products, the market acceptance of those
products, dependence on partners, successful performance under
collaborative and other commercial agreements, competition, the strength
of DARA's intellectual property, the intellectual property of others,
and other risk factors identified in the documents DARA has filed, or
will file, with the Securities and Exchange Commission. Copies of DARA's
filings with the SEC may be obtained from the SEC Internet site at
http://www.sec.gov.
DARA expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in DARA's expectations with
regard thereto or any change in events, conditions, or circumstances on
which any such statements are based. DARA BioSciences and the DARA logo
are trademarks of DARA BioSciences, Inc.
|
